search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Respiratory infections with Pseudomonas aeruginosa in children with Cystic Fibrosis; early surveillance and prevention.


- candidate number0
- NTR NumberNTR64
- ISRCTNISRCTN11604593
- Date ISRCTN created12-sep-2005
- date ISRCTN requested15-aug-2005
- Date Registered NTR12-jul-2005
- Secondary IDsN/A 
- Public TitleRespiratory infections with Pseudomonas aeruginosa in children with Cystic Fibrosis; early surveillance and prevention.
- Scientific TitleRespiratory infections with Pseudomonas aeruginosa in children with Cystic Fibrosis; early surveillance and prevention.
- ACRONYMPOPeye-study
- hypothesisOur hypothesis is that the initial infection with P. aeruginosa occurs at earlier age than previously reported and that prophylactic treatment of P. aeruginosa-negative CF-patients will either prevent or delay the first acquisition of P.aeruginosa or eradicate the organism before the onset of persistent colonization and accompanying pulmonary inflammatory response.
- Healt Condition(s) or Problem(s) studiedCystic Fibrosis (CF), Pulmonary P. aeruginosa infection
- Inclusion criteria1. CF diagnosis as confirmed by sweat chloride test and/or genotyping;
2. Age< 18 y;
3. No evidence of P. aeruginosa in cultures taken in period 2004-2005;
4. Antibody titer < 1: 1250 for three antigens of P. aeruginosa;
5. No regular treatment against P. aeruginosa;
6. Informed consent.
- Exclusion criteria1. Age > 18 years;
2. P. aeruginosa in cultures after 2003;
3. Participating in another trial.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type[default]
- Studytypeintervention
- planned startdate 1-jul-2005
- planned closingdate1-nov-2008
- Target number of participants100
- InterventionsCiprofloxacin 10 mg/kg po. or matching placebo bid & colistin 1 MIU inhalation or matching placebo bid; 3-monthly courses of 3 weeks, total study duration 3 years.
- Primary outcomeEarly P. aeruginosa colonization as confirmed by
-persistence of P. aeruginosa in sputum or oropharygeal swab culture in two consecutive samples, taken > 3 days apart;
-P. aeruginosa in one oropharyngeal swab or sputum culture with pulmonary exacerbation.
- Secondary outcomeMICROBIOLOGICAL:
1. Age at first positive culture;
2. Time to P. aeruginosa colonisation;
3. Respiratory pathogens in culture;
4. Resistance pattern of respiratory pathogens.
SEROLOGICAL:
5. Seroconversion for anti-pseudomonal antibodies;
CLINICAL:
6. Adverse events;
7. Clinical parameters (lung function, body weight and chest radiograph scores, inflammation parameters);
8. Number of pulmonal exacerbations;
9. Antimicrobial agent use.
- Timepoints
- Trial web sitehttp://www.CF-centrum.nl
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESDrs. Gerdien A. Tramper-Stranders
- CONTACT for SCIENTIFIC QUERIESDrs. Gerdien A. Tramper-Stranders
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Utrecht (UMCU)
- PublicationsA controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
G.A. Tramper-Stranders, T.F.W. Wolfs, S. van Haren Noman, W.M.C. van Aalderen, A.F. Nagelkerke, M. Nuijsink, J.L.L. Kimpen, C.K. van der Ent.
Thorax 2010 Oct;65:915-20
- Brief summaryCystic fibrosis (CF) is an autosomal recessive disease characterized by chronic obstructive pulmonary disease with recurrent respiratory tract infections. Chronic colonization with P. aeruginosa is a major cause of progressive loss of lung function, morbidity and mortality. Initial acquisition and transient colonization is transformed into an irreversible chronic colonization with antibiotic-resistent bacteria embedded in a biofilm in about 12 months. The prevalence of P. aeruginosa colonization increases from 20% of patients by age 1 until 80-85% by age 20. Early antimicrobial treatment of initial infection probably delays chronic colonization. However, diagnosis of P.aeruginosa infection with traditionally performed oropharyngeal cultures is insensitive and colonization of P.aeruginosa often reappears after interruption of antimicrobial treatment.
Our hypothesis is that the initial infection with P. aeruginosa occurs at earlier age than previously reported and that prophylactic treatment of P. aeruginosa-negative CF-patients will either prevent or delay the first acquisition of P.aeruginosa or eradicate the organism before the onset of persistent colonization and accompanying pulmonary inflammatory response.
Serological evaluation for anti-pseudomonal antibodies and culture of sputum will be performed in addition to the traditional oropharyngeal cultures to improve early P.aeruginosa detection. A 3-years randomized, placebo-controlled trial will be performed in P. aeruginosa- negative CF patients to evaluate the effect of three-monthly courses of inhaled colistin (106 IU b.i.d) and oral ciprofloxacin (20 mg/kg/day) on the acquisition of P. aeruginosa.
The present project aims to early identify P.aeruginosa infection in the course of CF and to find support for the use of prophylactic antimicrobial treatment to prevent or delay the early colonization of P. aeruginosa to preserve lung function.
Study questions:
1. Can the sensitivity of the surveillance of initial P. aeruginosa infection in children with CF be improved by measurement of anti-Pseudomonal antibodies?
2. Can the initial P. aeruginosa infection or early colonization be prevented or delayed by the prophylactic treatment of 3-monthly courses of inhaled colistin and oral ciprofloxacin?
3. What are the determinants for P.aeruginosa acquisition in children with CF?
- Main changes (audit trail)
- RECORD3-aug-2005 - 21-jan-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl
  • Dit zijn de gegevens waarmee uw trial is aangemeld en geregistreerd in het Nederlands Trial Register